New strategies for the treatment of chronic rejection

Current Opinion in Investigational Drugs

Volumn 5, Issue 5, 2004, Pages 489-498

  Hoerbelt, Ruediger ^a   Muniappan, Ashok ^a   Madsen, Joren C ^a,b   Allen, James S ^a,c,d  

^a Department of Surgery   (United States)

^b Division of Cardiac Surgery   (Canada)

^c Department of Surgery   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chronic; Immunosuppression; Rejection; Tolerance; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ALLOTRANSPLANTATION; CHEMISTRY; CHRONIC DISEASE; GRAFT REJECTION; HUMAN; IMMUNOLOGY; REVIEW; STRUCTURE ACTIVITY RELATION;

CHRONIC DISEASE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HOMOLOGOUS;

EID: 3342878380     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Hertz MI, Mohacsi PJ, Taylor DO, Trulock EP, Boucek MM, Deng MC, Keck BM, Edwards LB, Rowe AW: The Registry of the International Society for Heart and Lung Transplantation: Introduction to the Twentieth Annual Reports - 2003. J Heart Lung Transplant (2003) 22(6):610-615.
2. Cecka JM: The UNOS Scientific Renal Transplant Registry - 2000. Clin Transpl (2000):1-18.
3. Mazzucco G, Motta M, Segoloni G, Monga G: Intertubular capillary changes in the cortex and medulla of transplanted kidneys and their relationship with transplant glomerulopathy: An ultrastructural study of 12 transplantectomies. Ultrastruct Pathol (1994) 18(6):533-537.
4. Womer KL, Vella JP, Sayegh MH: Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol (2000) 20(2):126-147.
5. Legendre C, Thervet E, Skhiri H, Mamzer-Bruneel MF, Cantarovich F, Noel LH, Kreis H: Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation (1998) 65(11):1506-1509.
6. Waaga AM, Gasser M, Laskowski I, Tilney NL: Mechanisms of chronic rejection. Curr Opin Immunol (2000) 12(5):517-521.
7. Humar A, Kerr S, Gillingham KJ, Matas AJ: Features of acute rejection that increase risk for chronic rejection. Transplantation (1999) 68(8):1200-1203.
8. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, Gores PF, Gruessner RW, Najarian JS: Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation (1993) 55(5):993-995.
9. Almond PS, Matas A, Gillingham K, Dunn DL, Payne WD, Gores P, Gruessner R, Najarian JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation (1993) 55(4):752-756.
10. Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med (1998) 338(25):1813-1821.
11. Lechler RI, Lombardi G, Batchelor JR, Reinsmoen NL, Bach FH: The molecular basis of alloreactivity. Immunol Today (1990) 11(3):83-88.
12. Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH: Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: Potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol (2002) 13(1):252-259.
13. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI: Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy. J Immunol (2001) 167(12):7199-7206.
14. Cecka JM: The UNOS Scientific Renal Transplant Registry - ten years of kidney transplants. Clin Transpl (1997):1-14.
15. SivaSai KS, Smith MA, Poindexter NJ, Sundaresan SR, Trulock EP, Lynch JP, Cooper JD, Patterson GA, Mohanakumar T: Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation (1999) 67(8):1094-1098.
16. Smith MA, Jaramillo A, SivaSai KS, Naziruddin B, Kaleem Z, Patterson GA, Mohanakumar T: Indirect recognition and antibody production against a single mismatched HLA-A2-transgenic molecule precede the development of obliterative airway disease in murine heterotopic tracheal allografts. Transplantation (2002) 73(2):186-193.
17. Vella JP, Magee C, Vos L, Womer K, Rennke H, Carpenter CB, Hancock W, Sayegh MH: Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation (1999) 67(12):1523-1532.
18. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH: Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol (2001) 12(11):2500-2506.
19. Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC: Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci USA (2001) 98(6):3276-3281.
20. Ciubotariu R, Liu Z, Colovai AI, Ho E, Itescu S, Ravalli S, Hardy MA, Cortesini R, Rose EA, Suciu-Foca N: Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest (1998) 101(2):398-405.
21. Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, Mancini D, Rose EA, Cortesini R, Michler RE, Suciu-Foca N: Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest (1996) 98(5):1150-1157.
22. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, Sayegh MH: Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation (1997) 64(6):795-800.
23. Davenport A, Younie ME, Parsons JE, Klouda PT: Development of cytotoxic antibodies following renal allograft transplantation is associated with reduced graft survival due to chronic vascular rejection. Nephrol Dial Transplant (1994) 9(9):1315-1319.
24. Abe M, Kawai T, Futatsuyama K, Tanabe K, Fuchinoue S, Teraoka S, Toma H, Ota K: Postoperative production of anti-donor antibody and chronic rejection in renal transplantation. Transplantation (1997) 63(11):1616- 1619.
25. Jeannet M, Pinn VW, Flax MH, Winn HJ, Russell PS: Humoral antibodies in renal allotransplantation in man. N Engl J Med (1970) 282(3):111-117.
26. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, Williams WW, Cosimi AA, Schneeberger EE, Colvin RB: Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 12(3):574-582.
27. Russell ME: Macrophages in chronic rejection and graft vasculopathy: A diverse and dynamic cell with myriad roles. Transplantation Rev (1999) 13:157-168.
28. Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, Lorber MI, Pober JS: Interferon-γ elicits arteriosclerosis in the absence of leukocytes. Nature (2000) 403(6766):207-211.
29. Russell PS, Chase CM, Sykes M, Ito H, Shaffer J, Colvin RB: Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol (2001) 167(10):5731-5740.
30. Fedoseyeva EV, Zhang F, Orr PL, Levin D, Buncke HJ, Benichou G: De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol (1999) 162(11):6836-6842.
31. Haque MA, Mizobuchi T, Yasufuku K, Fujisawa T, Brutkiewicz RR, Zheng Y, Woods K, Smith GN, Cummings OW, Heidler KM, Blum JS et al: Evidence for immune responses to a self-antigen in lung transplantation: Role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol (2002) 169(3):1542-1549.
32. Jurcevic S, Ainsworth ME, Pomerance A, Smith JD, Robinson DR, Dunn MJ, Yacoub MH, Rose ML: Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation (2001) 71(7):886-892.
33. Paul LC: Immunologic risk factors for chronic renal allograft dysfunction. Transplantation (2001) 71(11 Suppl):SS17-SS23.
34. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ: The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Report-2001. J Heart Lung Transplant (2001) 20(8):805-815.
35. Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, Arfors KE, Messmer K: The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation (1994) 57(2):211-217.
36. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL: The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest (1997) 100(5):1199-1203.
37. Fujinami RS, Nelson JA, Walker L, Oldstone MB: Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR β chain: A means for graft rejection and immunosuppression. J Virol (1988) 62(1):100-105.
38. Beck S, Barrell BG: Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature (1988) 331(6153):269-272.
39. Brenner BM, Milford EL: Nephron underdosing: A programmed cause of chronic renal allograft failure. Am J Kidney Dis (1993) 21(5 Suppl 2):66-72.
40. Halloran PF, Melk A, Barth C: Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol (1999) 10(1):167-181.
41. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, Chandraker A, Sayegh MH, Tilney NL: Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation (1998) 65(12):1533-1542.
42. Wilhelm MJ, Pratschke J, Beato F, Taal M, Laskowski IA, Paz DM, Schmid C, Hancock WW, Scheld HH, Tilney NL: Activation of proinflammatory mediators in heart transplants from brain-dead donors: Evidence from a model of chronic rat cardiac allograft rejection. Transplant Proc (2002) 34(6):2359-2360.
43. Kahan BD: Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplantation (2001) 71(Suppl 11):SS52-SS57.
44. Finckenberg P, Lassila M, Inkinen K, Pere AK, Krogerus L, Lindgren L, Mervaala E, Vapaatalo H, Nurminen ML, Ahonen J: Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation (2001) 71(7):951-958.
45. Chen W, Thoburn CJ, Miura Y, Sommer M, Hruban R, Qian Z, Baldwin W, Hess AD: Autoimmune-mediated vasculopathy. Clin Immunol (2001) 100(1):57-70.
46. Smiley ST, Csizmadia V, Gao W, Turka LA, Hancock WW: Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFκB: Implications for tolerance induction. Transplantation (2000) 70(3):415-419.
47. Yamada K, Gianello PR, Ierino FL, Fishbein J, Lorf T, Shimizu A, Colvin RB, Sachs DH: Role of the thymus in transplantation tolerance in miniature swine: II. Effect of steroids and age on the induction of tolerance to class I mismatched renal allografts. Transplantation (1999) 67(3):458-467.
48. Denton MD, Magee CC, Sayegh MH: Immunosuppressive strategies in transplantation. Lancet (1999) 353(9158):1083-1091.
49. Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis (1999) 34(2):296-303.
50. Mathew TH: A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1998) 65(11):1450-1454.
51. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation (1999) 68(3):391-396.
52. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation (2000) 69(11):2405-2409.
53. Fujihara CK, Malheiros DM, Zatz R, Noronha ID: Mycophenolate mofetil attenuates renal injury in the rat remnant kidney. Kidney Int (1998) 54(5):1510-1519.
54. Morris RE, Meiser BM: Identification of a new pharmacologic action for an old compound. Med Sci Res (1989) 17:609.
55. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ, Thiru S: Rapamycin for immunosuppression in organ allografting. Lancet (1989) 2(8656):227.
56. Henderson DJ, Naya I, Bundick RV, Smith GM, Schmidt JA: Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunology (1991) 73(3):316-321.
57. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G, Schreiber SL: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci USA (1990) 87(23):9231-9235.
58. S6 kinase. Nature (1992) 358(6381):70-73.
59. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE: Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science (1992) 257(5072):973-977.
60. Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem (1995) 270(2):815-822.
61. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE: Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation (1995) 59(3):390-395.
62. Marx SO, Jayaraman T, Go LO, Marks AR: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res (1995) 76(3):412-417.
63. Mohacsi PJ, Tuller D, Hulliger B, Wijngaard PL: Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant (1997) 16(5):484-492.
64. Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U, Berry GJ, Yock PG, Morris RE: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation (2000) 70(6):969-975.
65. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation (2002) 74(8):1070-1076.
66. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA, Starling RC, Sorensen K, Hummel M, Lind JM, Abeywickrama KH et al: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med (2003) 349(9):847-858.
67. Mancini D, Pinney S, Burkhoff D, LaManca J, Itescu S, Burke E, Edwards N, Oz M, Marks AR: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation (2003) 108(1):48-53.
68. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Cohen AH, Teraski PI: The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation (1996) 61(10):1469-1474.
69. Meiser BM, Wenke K, Thiery J, Wolf S, Devens C, Seidel D, Hammer C, Billingham ME, Reichart B: Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transplant Proc (1993) 25(2):2077-2079.
70. Katznelson S: Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Kidney Int Suppl (1999) 71:S117-S121.
71. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 333(10):621-627.
72. Hardinger KL, Wang CD, Schnitzler MA, Miller BW, Jendrisak MD, Shenoy S, Lowell JA, Brennan DC: Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant (2002) 2(9):867-871.
73. Williams JW, Mital D, Chong A, Kottayil A, Millis M, Longstreth J, Huang W, Brady L, Jensik S: Experiences with leflunomide in solid organ transplantation. Transplantation (2002) 73(3):358-366.
74. Savikko J, von Willebrand E, Hayry P: Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: Potential applications for restenosis and chronic rejection. Transplantation (2003) 76(3):455-458.
75. Pan F, Ebbs A, Wynn C, Erickson L, Jang MS, Crews G, Fisniku O, Kobayashi M, Paul LC, Benediktsson H, Jiang AH: FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. Transplantation (2003) 75(8):1110-1114.
76. Auchincloss H Jr: In search of the elusive Holy Grail: The mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant (2001) 1(1):6-12.
77. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA: Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J Immunol (2001) 166(2):973-981.
78. Helg C, Chapuis B, Bolle J-F, Morel P, Salomon D, Roux E, Antonioli V, Jeannet M, Leski M: Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation (1994) 58(12):1420-1422.
79. Ildstad ST, Sachs DH: Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 307(5947):168-170.
80. Kawai T, Poncelet A, Sachs DH, Mauiyyedi S, Boskovic S, Wee SL, Ko DS, Bartholomew A, Kimikawa M, Hong HZ, Abrahamian G et al: Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of renal allograft tolerance. Transplantation (1999) 68(11):1767-1775.
81. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL: Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med (1991) 114(11):954-955.
82. Wekerle T, Sykes M: Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation (1999) 68(4):459-467.
83. Kawai T, Cosimi AB, Colvin RB, Powelson J, Eason J, Kozlowski T, Sykes M, Monroy R, Tanaka M, Sachs DH: Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 59(2):256-262.
84. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB: Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation (1997) 64(5):709-716.
85. Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sackstein R, Saidman S, Colby C, Sykes M, Sachs DH, Cosimi AB: Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 68(4):480-484.
86. Buhler LH, Spitzer TR, Sykes M, Sachs DH, Delmonico FL, Tolkoff-Rubin N, Saidman SL, Sackstein R, McAfee S, Dey B, Colby C et al: Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation (2002) 74(10):1405-1409.
87. Kawai T, Cosimi AB, Wee SL, Houser S, Andrews D, Sogawa H, Phelan J, Boskovic S, Nadazdin O, Abrahamian G, Colvin RB et al: Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. Transplantation (2002) 73(11):1757-1764.
88. Schwarze ML, Menard MT, Fuchimoto Y, Huang CA, Houser S, Mawulawde K, Allison KS, Sachs DH, Madsen JC: Mixed hematopoietic chimerism induces long-term tolerance to cardiac allografts in miniature swine. Ann Thorac Surg (2000) 70(1):131-138.
89. Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature (1953) 172(4379):603-606.
90. Madsen JC: Tailoring tolerance to prevent chronic rejection. Transplantation (2001) 72(8 Suppl):S10-S12.
91. Sykes M: Mixed chimerism and transplant tolerance. Immunity (2001) 14(4):417-424.
92. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 356(6370):607-609.
93. Van Parijs L, Abbas AK: Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science (1998) 280(5361):243- 248.
94. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med (1991) 174(3):561-569.
95. Sayegh MH, Zheng X-G, Magee C, Hancock WW, Turka LA: Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation (1997) 64(12):1646-1650.
96. Shirasugi N, Adams AB, Durham MM, Lukacher AE, Xu H, Rees P, Cowan SR, Williams MA, Pearson TC, Larsen CP: Prevention of chronic rejection in murine cardiac allografts: A comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol (2002) 169(5):2677-2684.
97. Li Y, Li XC, Zheng XX, Wells AD, Turka LA, Strom TB: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med (1999) 5(11):1298-1302.
98. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med (2000) 192(9):1213-1222.
99. Dhodapkar MV, Steinman RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood (2002) 100(1):174-177.
100. Gianello PR, Fishbein JM, Rosengard BR, Lorf T, Vitiello DM, Arn JS, Sachs DH: Tolerance to class I-disparate renal allografts in miniature swine. Maintenance of tolerance despite induction of specific antidonor CTL responses. Transplantation (1995) 59(5):772-777.
101. Utsugi R, Lee RS, Barth RN, Kitamura H, Sachs DH, Yamada K: Mechanisms of tacrolimus induced tolerance to fully MHC-mismatched renal allografts in miniature swine: Donor antigen specific regulatory mechanisms. Transplantation (2000) 69:S124-S125.
102. Ierino FL, Yamada K, Hatch T, Rembert J, Sachs DH: Peripheral tolerance to class I mismatched renal allografts in miniature swine: Donor antigen-activated peripheral blood lymphocytes from tolerant swine inhibit antidonor CTL reactivity. J Immunol (1999) 162(1):550-559.
103. Madsen JC, Yamada K, Allan JS, Choo JK, Erhorn AE, Pins MR, Vesga L, Slisz JV, Sachs DH: Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation (1998) 65(3):304-313.
104. Koshiba T, Van Damme B, Rutgeerts O, Waer M, Pirenne J: FTY720, an immunosuppressant that alters lymphocyte trafficking, abrogates chronic rejection in combination with cyclosporine A. Transplantation (2003) 75(7):945-952.
105. Dosanjh A, Ikonen T, Wan B, Morris RE: Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. Pulm Pharmacol Ther (2002) 15(5):433-437.
106. Bedard EL, Kim P, Jiang J, Parry N, Liu L, Wang H, Garcia B, Li X, McFadden G, Lucas A, Zhong R: Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts. Transplantation (2003) 76(1):249-252.
107. Yun JJ, Fischbein MP, Whiting D, Irie Y, Fishbein MC, Burdick MD, Belperio J, Strieter RM, Laks H, Berliner JA, Ardehali A: The role of MIG/CXCL9 in cardiac allograft vasculopathy. Am J Pathol (2002) 161(4):1307-1313.
108. Savikko J, Taskinen E, von Willebrand E: Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: Tyrosine kinase inhibitors as a potential therapy. Transplantation (2003) 75(8):1147-1153.
109. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S et al: Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med (2003) 9(2):183-190.
110. Tullius SG, Nieminen-Kelha M, Buelow R, Reutzel-Selke A, Martins PN, Pratschke J, Bachmann U, Lehmann M, Southard D, Iyer S, Schmidbauer G et al: Inhibition of ischemia/reperfusion injury and chronic graft deterioration by a single-donor treatment with cobalt-protoporphyrin for the induction of heme oxygenase-1. Transplantation (2002) 74(5):591-598.
111. Chauveau C, Bouchet D, Roussel JC, Mathieu P, Braudeau C, Renaudin K, Tesson L, Soulillou JP, Iyer S, Buelow R, Anegon I: Gene transfer of heme oxygenase-1 and carbon monoxide delivery inhibit chronic rejection. Am J Transplant (2002) 2(7):581-592.